Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Biogen

World's first EVER drug shown to work against Alzheimer's developed by scientists

Scientists say the development of the only drug to work against Alzheimer’s is a 'historic moment' - with regulators expected to approve the groundbreaking drug by the New Year

Daily Mirror

Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

Benzinga

Alzheimer’s progression slowed by drug in major trial

Eisai Co. and partner Biogen Inc. said their Alzheimer’s drug significantly slowed the disease, making it the first medicine to clearly blunt progression of the most common type of dementia in a definitive, large-scale trial.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

Check Out What Whales Are Doing With BIIB

A whale with a lot of money to spend has taken a noticeably bullish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 19 strange trades.

Benzinga

Biogen pays $900M to settle doctor kickback allegations

Biogen has agreed to pay $900 million to resolve allegations that it violated federal law by paying kickbacks to doctors in the form of speakers and consulting fees to persuade them to prescribe its multiple sclerosis drugs

The Independent UK

Rugby legends hail Motor Neurone Disease breakthrough that 'will bring hope to thousands'

A breakthrough in MND treatment has been described as 'remarkable’ as rugby greats Doddie Weir and Rob Burrow - both diagnosed with the condition - say there is hope for the future

Daily Mirror

Tofersen: ‘Truly remarkable’ drug slows down motor neurone disease, researchers find

Researchers say improvements reported with tofersen was ‘moment of hope’ for disease

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

‘Truly remarkable’ new drug slows motor neuron disease

Extended use of tofersen may help stabilise muscle strength and control, researchers say

The Independent UK

Experimental drug shows signs of slowing motor neurone disease

Biogen drug Tofersen showed promising results when taken for six months beyond previous trial

The Guardian - UK

‘Promising’ new drug shown to slow motor neurone disease progression

Extended use of tofersen may help stabilise muscle strength and control, researchers say.

The Independent UK

Looking At Biogen's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Biogen (NASDAQ:BIIB). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Biogen Whale Trades For September 14

Benzinga

What Are Whales Doing With Biogen

A whale with a lot of money to spend has taken a noticeably bearish stance on Biogen. Looking at options history for Biogen (NASDAQ:BIIB) we detected 28 strange trades.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

Critical elements of leading Alzheimer’s study possibly fraudulent

The highly influential paper, first published in 2006, has helped guide billions of dollars in US federal research into the disease

Benzinga

Biogen Whale Trades Spotted

Benzinga

EXCLUSIVE: Has Biotech Bottomed? NYSE Executive Floor Director Says Biogen And These 3 Stocks Look Poised To Outperform

Markets continue to trend lower amid rising inflation and Fed uncertainty, but one New York Stock Exchange floor director says the bottom may be in for a couple of beaten-down sectors.

Benzinga

Peering Into Biogen's Recent Short Interest

Biogen's (NASDAQ:BIIB) short percent of float has risen 9.27% since its last report. The company recently reported that it has 2.41 million shares sold short, which is 1.65% of all regular shares that are available for trading.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 3.63% on an annualized basis producing an average annual return of 10.11%. Currently, Biogen has a market capitalization of $31.20 billion.

StockNews.com

3 Biotech Stocks to Buy Now

Biotech stocks are starting to move higher as longer-term rates decline. The sector is very cheap with strong long-term fundamentals. Amgen (AMGN), Biogen (BIIB), and Bio-Techne (TECH) are 3 top biotech stocks that investors should consider buying.

Los Angeles Times

Commentary: Overhyped Alzheimer’s treatments betrayed patients’ hopes. Here’s how science should change

America’s science policies are changing. America’s scientists need to change with them. The recent controversies over the Food and Drug Administration’s accelerated approval of an Alzheimer’s treatment are a lesson in the costs of failing to do so.

Benzinga

The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Karyopharm Therapeutics' Shares Slide After Biogen Terminates 2018 Asset Purchase Agreement

Biogen Inc. (NASDAQ:BIIB) has informed Karyopharm Therapeutics Inc (NASDAQ:KPTI) that it has opted to terminate the companies' Asset Purchase Agreement dated January 24, 2018, as amended. As per the agreement, Karyopharm sold rights of its oral Selective Inhibitor of Nuclear Export compound KPT-350 and certain related assets to Biogen. KPTI received an upfront payment…

ABC News

Why the world's still waiting for a dementia cure, and what we can do in the meantime

Many researchers agree that Alzheimer's disease actually starts decades before thinking and memory start to decline. What can we do about it?

Benzinga

$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 2.47% on an annualized basis producing an average annual return of 9.5%. Currently, Biogen has a market capitalization of $30.05 billion.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.